This is the text extract for Notification Acitretin, Bezafibrate, Diazepam and Disulfiram Proposal, browse documents here.

23 February 2009

Acitretin, Bezafibrate, Diazepam and Disulfiram proposal approved

PHARMAC is pleased to announce the approval of a supply agreement with Actavis Australia Ltd for the supply of acitretin (Neotigason), bezafibrate (Bezalip Retard), diazepam (Stesolid) and disulfiram (Antabuse).

Summary of the decision

The subsidies and price for Neotigason, Bezalip Retard, and Stesolid will change in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 April 2009 as follows:

Chemical Acitretin Acitretin Bezafibrate Diazepam Diazepam Disulfiram Presentation Cap 10 mg Cap 25 mg Tab long-acting 400 mg Rectal tube 5 mg Rectal tube 10 mg Tab 200 mg Brand Neotigason Neotigason Bezalip Retard Stesolid Stesolid Antabuse Pack size 100 100 30 5 5 100 Current price and subsidy $94.75 $203.70 $7.60 $27.83 $33.89 $24.30 New price and subsidy $75.80 $162.96 $5.70 $25.05 $30.50 $24.30

Neotigason and Bezalip Retard will have subsidy and delisting protection until 30 June 2012. If you have any queries about this funding decision you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

What feedback was received?

No feedback was received in relation this proposal.

A263429 - T08-261

1 of 1